IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Subsequently, HHT was administered to 99 patients with early CML-CP using a dose schedule similar to that of the previous study of O’Brien et al., for six cycles, followed by the administration of IFN-a maintenance.